Literature DB >> 8203835

In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis.

B Fantin1, R Leclercq, M Ottaviani, J M Vallois, B Maziere, J Duval, J J Pocidalo, C Carbon.   

Abstract

We evaluated the in vivo activity and the diffusion of radiolabelled RP 57669 (RPI) and RP 54476 (RPII), the two components of the injectable streptogramin RP 59500, alone or in combination, in aortic vegetations from experimental endocarditis in rabbits. RPI and RPII demonstrated in vitro bacteriostatic and bactericidal synergy against a clinical strain of Staphylococcus aureus resistant to methicillin and susceptible to erythromycin. In experimental staphylococcal endocarditis, RP 59500 was as effective as vancomycin and significantly more effective than RPI (P < 0.01) and RPII (P < 0.05). Autoradiography studies showed different patterns of distribution into cardiac vegetations infected with Streptococcus sanguis for [14C]RPI and [14C]RPII. [14C]RPI was homogeneously distributed throughout the vegetations whereas [14C]RPII showed a decreasing gradient of concentration between the periphery and the core of the vegetation, with an approximately 2:1 ratio. [14C]RPI diffused approximately 2 to 4 times more than [14C]RPII into the core of the vegetations. Since the injected ratio of RPI and RPII is 30:70 in RP 59500, the actual RPI:RPII ratio in the core of the vegetation may range from 0.8 to 1.7, a ratio which remains compatible with the in vivo synergism demonstrated between the two components.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8203835      PMCID: PMC284476          DOI: 10.1128/AAC.38.3.432

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus.

Authors:  H F Chambers
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

2.  A phase I, double-blind, placebo-controlled study of the tolerance and pharmacokinetic behaviour of RP 59500.

Authors:  S D Etienne; G Montay; A Le Liboux; A Frydman; J J Garaud
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

3.  Post-antibiotic effects of RP 59500 with Staphylococcus aureus.

Authors:  A Nougayrede; N Berthaud; D H Bouanchaud
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

4.  In vitro antistaphylococcal activity and testing of RP 59500, a new streptogramin, by two methods.

Authors:  K E Aldridge; D D Schiro; L M Varner
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

5.  World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus.

Authors:  P A Maple; J M Hamilton-Miller; W Brumfitt
Journal:  Lancet       Date:  1989-03-11       Impact factor: 79.321

6.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

7.  3H-spiramycin penetration into fibrin vegetations in an experimental model of streptococcal endocarditis.

Authors:  A C Cremieux; J M Vallois; B Maziere; M Ottaviani; A Bouvet; C Carbon; J J Pocidalo
Journal:  J Antimicrob Chemother       Date:  1988-07       Impact factor: 5.790

8.  In-vitro and in-vivo synergic activity and fractional inhibitory concentration (FIC) of the components of a semisynthetic streptogramin, RP 59500.

Authors:  D H Bouanchaud
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

9.  Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography.

Authors:  A C Cremieux; B Maziere; J M Vallois; M Ottaviani; A Azancot; H Raffoul; A Bouvet; J J Pocidalo; C Carbon
Journal:  J Infect Dis       Date:  1989-05       Impact factor: 5.226

10.  Influence of low-level resistance to vancomycin on efficacy of teicoplanin and vancomycin for treatment of experimental endocarditis due to Enterococcus faecium.

Authors:  B Fantin; R Leclercq; M Arthur; J Duval; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

View more
  20 in total

Review 1.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis.

Authors:  A Saleh-Mghir; A Lefort; Y Petegnief; S Dautrey; J M Vallois; D Le Guludec; C Carbon; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 3.  Streptogramins. A unique class of antibiotics.

Authors:  J C Pechère
Journal:  Drugs       Date:  1996       Impact factor: 9.546

4.  Influence of resistance to streptogramin A type antibiotics on the activity of quinupristin-dalfopristin in vitro and in experimental endocarditis due to Staphylococcus aureus.

Authors:  V Zarrouk; B Bozdogan; R Leclercq; L Garry; C Carbon; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

5.  Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis.

Authors:  B Fantin; R Leclercq; L Garry; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

6.  Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics.

Authors:  V Zarrouk; B Bozdogan; R Leclercq; L Garry; C Feger; C Carbon; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

7.  Quinupristin-dalfopristin combined with beta-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolide-lincosamide-streptogramin B antibiotics.

Authors:  J Vouillamoz; J M Entenza; C Féger; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

8.  Comparison of antimicrobial agents as therapy for experimental endocarditis: caused by methicillin-resistant Staphylococcus aureus.

Authors:  Mustafa Sacar; Suzan Sacar; Nural Cevahir; Gokhan Onem; Zafer Teke; Ali Asan; Huseyin Turgut; Fahri Adali; Ilknur Kaleli; Ibrahim Susam; Yalin Tolga Yaylali; Ahmet Baltalarli
Journal:  Tex Heart Inst J       Date:  2010

9.  Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.

Authors:  M W Climo; R L Patron; B P Goldstein; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

10.  Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus.

Authors:  B Fantin; R Leclercq; Y Merlé; L Saint-Julien; C Veyrat; J Duval; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.